Engineered immune cells for cancers with GPC3 or mesothelin
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests a new type of immune cell therapy made from your own cells (gamma-delta T cells) that are engineered to find and attack cancers that have GPC3 or mesothelin proteins. It may be an option for people with advanced cancer who have not had gene therapy before and are in generally good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a specific protein (GPC3 or mesothelin) on its cells (your doctor can check this).
- You must be in good enough health to have a life expectancy of at least 3 months.
- Your heart, lungs, liver, kidneys, and blood counts should be working well enough.
- You must not have had gene therapy in the past.
- You must not have serious active infections, including hepatitis B, C, or HIV.
- You cannot be pregnant or breastfeeding, and you cannot be taking high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a customized immune therapy (CAR-T cells) for advanced cancers that have the proteins mesothelin, GPC3, and/or GUCY2C. It may help your body better recognize and kill cancer cells, but early-phase trials mainly focus on safety and learning how well the treatment works.
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
This study tests a new treatment called CAR T cells that target a protein called mesothelin found on certain cancer cells. The CAR T cells are made from your own immune cells and may help shrink tumors that have not responded to other therapies.
This Phase 1 study tests a personalized immune-cell treatment (CAR T cells) for advanced liver cancer that has the GPC3 protein. It aims to see whether these engineered cells can find and kill cancer cells safely and help shrink the cancer.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.